vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
TOMPKINS FINANCIAL CORP is the larger business by last-quarter revenue ($194.8M vs $139.2M, roughly 1.4× ADMA BIOLOGICS, INC.). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 35.5%, a 13.9% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 18.4%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $31.9M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 30.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
ADMA vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $194.8M |
| Net Profit | $49.4M | $96.2M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | 71.7% |
| Net Margin | 35.5% | 49.4% |
| Revenue YoY | 18.4% | 152.7% |
| Net Profit YoY | -55.9% | 388.9% |
| EPS (diluted) | $0.20 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $194.8M | ||
| Q3 25 | $134.2M | $87.4M | ||
| Q2 25 | $122.0M | $82.6M | ||
| Q1 25 | $114.8M | $81.7M | ||
| Q4 24 | $117.5M | $77.1M | ||
| Q3 24 | $119.8M | $76.6M | ||
| Q2 24 | $107.2M | $72.7M | ||
| Q1 24 | $81.9M | $72.8M |
| Q4 25 | $49.4M | $96.2M | ||
| Q3 25 | $36.4M | $23.7M | ||
| Q2 25 | $34.2M | $21.5M | ||
| Q1 25 | $26.9M | $19.7M | ||
| Q4 24 | $111.9M | $19.7M | ||
| Q3 24 | $35.9M | $18.6M | ||
| Q2 24 | $32.1M | $15.7M | ||
| Q1 24 | $17.8M | $16.9M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — | ||
| Q1 24 | 47.8% | — |
| Q4 25 | 45.1% | 71.7% | ||
| Q3 25 | 38.0% | 35.6% | ||
| Q2 25 | 35.1% | 34.2% | ||
| Q1 25 | 30.4% | 31.6% | ||
| Q4 24 | 32.6% | 33.4% | ||
| Q3 24 | 33.1% | 32.0% | ||
| Q2 24 | 36.6% | 28.3% | ||
| Q1 24 | 26.7% | 30.4% |
| Q4 25 | 35.5% | 49.4% | ||
| Q3 25 | 27.1% | 27.1% | ||
| Q2 25 | 28.1% | 26.0% | ||
| Q1 25 | 23.4% | 24.1% | ||
| Q4 24 | 95.2% | 25.5% | ||
| Q3 24 | 30.0% | 24.3% | ||
| Q2 24 | 29.9% | 21.6% | ||
| Q1 24 | 21.7% | 23.2% |
| Q4 25 | $0.20 | $6.72 | ||
| Q3 25 | $0.15 | $1.65 | ||
| Q2 25 | $0.14 | $1.50 | ||
| Q1 25 | $0.11 | $1.37 | ||
| Q4 24 | $0.45 | $1.39 | ||
| Q3 24 | $0.15 | $1.30 | ||
| Q2 24 | $0.13 | $1.10 | ||
| Q1 24 | $0.08 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $132.8M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $938.4M |
| Total Assets | $624.2M | $8.7B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $132.8M | ||
| Q3 25 | $61.4M | $193.5M | ||
| Q2 25 | $90.3M | $212.6M | ||
| Q1 25 | $71.6M | $193.1M | ||
| Q4 24 | $103.1M | $134.4M | ||
| Q3 24 | $86.7M | $132.3M | ||
| Q2 24 | $88.2M | $70.9M | ||
| Q1 24 | $45.3M | $57.1M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $938.4M | ||
| Q3 25 | $431.2M | $788.8M | ||
| Q2 25 | $398.3M | $761.8M | ||
| Q1 25 | $373.4M | $741.4M | ||
| Q4 24 | $349.0M | $713.4M | ||
| Q3 24 | $231.9M | $719.9M | ||
| Q2 24 | $188.3M | $674.6M | ||
| Q1 24 | $153.7M | $667.9M |
| Q4 25 | $624.2M | $8.7B | ||
| Q3 25 | $568.7M | $8.5B | ||
| Q2 25 | $558.4M | $8.4B | ||
| Q1 25 | $510.6M | $8.2B | ||
| Q4 24 | $488.7M | $8.1B | ||
| Q3 24 | $390.6M | $8.0B | ||
| Q2 24 | $376.4M | $7.9B | ||
| Q1 24 | $350.9M | $7.8B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $38.9M |
| Free Cash FlowOCF − Capex | $34.6M | $31.9M |
| FCF MarginFCF / Revenue | 24.8% | 16.4% |
| Capex IntensityCapex / Revenue | 0.8% | 3.6% |
| Cash ConversionOCF / Net Profit | 0.72× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $38.9M | ||
| Q3 25 | $13.3M | $34.9M | ||
| Q2 25 | $21.1M | $18.9M | ||
| Q1 25 | $-19.7M | $22.2M | ||
| Q4 24 | $50.2M | $95.0M | ||
| Q3 24 | $25.0M | $21.2M | ||
| Q2 24 | $45.6M | $27.3M | ||
| Q1 24 | $-2.2M | $23.2M |
| Q4 25 | $34.6M | $31.9M | ||
| Q3 25 | $-1.1M | $33.9M | ||
| Q2 25 | $18.7M | $18.3M | ||
| Q1 25 | $-24.4M | $20.9M | ||
| Q4 24 | $47.5M | $88.8M | ||
| Q3 24 | $24.0M | $18.9M | ||
| Q2 24 | $43.6M | $26.3M | ||
| Q1 24 | $-4.6M | $21.9M |
| Q4 25 | 24.8% | 16.4% | ||
| Q3 25 | -0.8% | 38.8% | ||
| Q2 25 | 15.3% | 22.1% | ||
| Q1 25 | -21.2% | 25.5% | ||
| Q4 24 | 40.4% | 115.1% | ||
| Q3 24 | 20.0% | 24.7% | ||
| Q2 24 | 40.7% | 36.2% | ||
| Q1 24 | -5.6% | 30.0% |
| Q4 25 | 0.8% | 3.6% | ||
| Q3 25 | 10.7% | 1.1% | ||
| Q2 25 | 2.0% | 0.8% | ||
| Q1 25 | 4.1% | 1.7% | ||
| Q4 24 | 2.3% | 8.1% | ||
| Q3 24 | 0.9% | 2.9% | ||
| Q2 24 | 1.9% | 1.3% | ||
| Q1 24 | 2.9% | 1.9% |
| Q4 25 | 0.72× | 0.40× | ||
| Q3 25 | 0.36× | 1.47× | ||
| Q2 25 | 0.62× | 0.88× | ||
| Q1 25 | -0.73× | 1.13× | ||
| Q4 24 | 0.45× | 4.82× | ||
| Q3 24 | 0.70× | 1.14× | ||
| Q2 24 | 1.42× | 1.74× | ||
| Q1 24 | -0.12× | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
TMP
Segment breakdown not available.
